Q2 2025 Bioharvest Sciences Inc Earnings Call Transcript
Key Points
- Revenue increased by 41% year-over-year to $8.5 million, driven by balanced performance across vinia.com and Amazon, and contributions from the CDMO services division.
- Gross margins expanded by 800 basis points to 60%, reflecting scale and technology leverage, including the deployment of larger bioreactors and improved manufacturing yields.
- The VINIA product line has maintained premium pricing with high customer retention and a 4.7-star average rating, nearing 10,000 customer reviews.
- The company launched new products, including VINIA Daily 2X Formula chews and SuperFood Tea SKUs, contributing to 20% of incremental revenue growth.
- The CDMO division achieved significant milestones, including advancing a pharmaceutical project to Stage 2 and signing a new contract targeting a fragrance molecule.
- Net losses for the second quarter totaled $4 million, a significant increase from the $0.7 million loss in the same quarter last year.
- Operating expenses increased to $6.9 million from $4.8 million, driven by higher marketing spend and development costs for the Health Pros' Affiliate program.
- General and administration expenses rose by 61% due to one-time costs associated with NASDAQ corporate compliance upgrades.
- The adjusted EBITDA loss was $1.3 million, slightly higher than the $1.2 million loss in the same quarter last year.
- The company faces potential impacts from tariffs on materials transferred from Israel to the US, although these have been managed through cost efficiencies.
Greetings, and welcome to the BioHarvest Sciences second quarter 2025 corporate update conference call. (Operator Instructions) As a reminder, this conference is being recorded.
Before we begin the formal presentation, I'd like to remind everyone that statements made on today's call and webcast, including those regarding future financial results and industry prospects are forward-looking and may be subject to a number of risks and uncertainties that could cause actual results to differ materially from those described on the call.
Please refer to the company's regulatory filings for a list of associated risks, and we would also refer you to the company's website for more supporting industry information. In addition, throughout today's call, the company may refer to adjusted EBITDA, a non-IFRS financial measure, which it believes provides helpful information to investors about the performance on the business on an ongoing basis.
A reconciliation of adjusted EBITDA to its most directly comparable IFRS financial measure is included in today's earnings release, which is available on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
